Glucagen Hypokit

Glucagen Hypokit is a prescription medication that contains the peptide hormone glucagon as its active ingredient. It is supplied in a kit format for emergency use, though specific strength and dosage form are not disclosed. The product is marketed in the European Union and is administered by intramuscular, intravenous, or subcutaneous injection to promptly and effectively raise blood glucose levels in patients experiencing severe hypoglycemia.

Glucagen Hypokit is indicated for the treatment of severe hypoglycemia when rapid restoration of blood glucose is required.

- Emergency treatment of insulin‑induced hypoglycemia in diabetic patients. - Management of hypoglycemia unawareness where oral carbohydrate intake is insufficient. - Use in a clinical setting when intravenous dextrose is unavailable or delayed. - Administration by trained personnel during a hypoglycemic crisis in outpatient or home environments.

The safety profile of glucagon includes both frequently observed and less common adverse reactions.

Common: - Nausea or vomiting. - Headache. - Flushing or warmth. - Injection‑site pain or bruising. - Transient hyperglycemia. - Dizziness.

Serious: - Allergic reactions including rash or urticaria. - Anaphylaxis. - Cardiovascular events such as tachycardia or arrhythmia. - Severe hyperglycemia leading to osmotic diuresis. - Hypotension. - Pulmonary edema in susceptible individuals.

Before using Glucagen Hypokit, healthcare providers should consider several precautionary measures to ensure safe administration.

- Verify diagnosis of severe hypoglycemia before injection. - Assess for known hypersensitivity to glucagon or any kit components. - Use caution in patients with pheochromocytoma or adrenal insufficiency. - Monitor cardiac status in patients with recent myocardial infarction. - Avoid use in patients with severe renal impairment without specialist advice. - Ensure proper storage conditions to maintain peptide stability.

Glucagon may interact with other medications, influencing its effectiveness or safety.

Avoid: - Concurrent use of beta‑blockers may blunt the hyperglycemic response. - Combination with insulin secretagogues can increase risk of recurrent hypoglycemia.

Use with caution: - Concomitant use of catecholamines may augment cardiovascular effects. - Co‑administration with oral hypoglycemic agents requires close glucose monitoring. - Interaction with corticosteroids may affect glucose metabolism. - Use alongside other vasoactive agents should be supervised by a clinician.